Please login to the form below
Fasenra
This page shows the latest Fasenra news and features for those working in and with pharma, biotech and healthcare.
AZ raises full-year guidance after completing Alexion acquisition in Q2
AstraZeneca has delivered another period of strong growth thanks to robust performances across all regions and disease areas, particularly oncology, new CVRM and Fasenra in respiratory.
Latest news
-
AZ forecasts growth in 2021 after revenues surge in Q4
medicines such as Imfinzi and monoclonal antibody Fasenra (benralizumab).
-
AZ, Amgen’s investigational asthma drug comes good in phase 3
AZ’s own interleukin-5 inhibitor (IL-5) Fasenra (benralizumab) is approved as an add-on maintenance treatment for eosinophilic asthma, while another IL-5 inhibitor from GlaxoSmithKline’s IL-5
-
Novartis strengthens case for its combination asthma drug
as AstraZeneca’s asthma injection Fasenra(benralizumab).
-
Nucala works in rare inflammatory disease, says GSK
GSK is trying to keep the first-to-market IL-5 inhibitor ahead of other drugs in the class, particularly AstraZeneca’s Fasenra (benralizumab) which is gaining ground fast with
-
AZ reports growth again in Q3, driven by oncology and China sales
AZ’s respiratory franchise also grew 18% to $1.3bn – although the company saw a 4% decline in sales of Symbicort, this was offset by the growth of Pulmicort and Fasenra,
More from news
Approximately 7 fully matching, plus 19 partially matching documents found.
Latest Intelligence
-
The long and winding road to asthma breakthroughs
But GSK is not alone in the IL-5 inhibitor arena. AstraZeneca’s Fasenra is making waves with its eight-week dosing schedule and $296m in first-half sales – a 244%
-
AstraZeneca: building a new ‘open innovation’ pharma company
AstraZeneca launched five significant new medicines in 2017: immunotherapy Iminzi, Calquence for mantle cell lymphoma, Qtern in type 2 diabetes, Bevespi Aerosphere in COPD and Fasenra for severe asthma.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO
Since joining MedImmune in 2006, Bahija has overseen the development of several new medicines, including Imfinzi, Fasenra, Lumoxiti, Siliq and FluMist Quadrivalent.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
-
B2B media account director
-
Competitive salary
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- First trial of a vaccine against Alzheimer’s launches
- First von Willebrand disease therapy heads new FDA approvals
- Sanofi to buy acne specialist Origimm
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- David Hunt launches independent agency The Considered
PMHub
W2O Group
W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...
Latest intelligence
- Diversity in clinical trials: looking back at our 2021 blogs
- In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
- What does the future hold for Light-chain Amyloidosis?
- Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
- Webinar:
- Securing a future for telehealth with immersive market research insights...
